a public good project by the
Synthesis
Company
of California

© 2026

Gregory A. Wiseman | doi.page

0 works0 citations0 h-index

Gregory A. Wiseman

WinnMed(US)Mayo Clinic in Arizona(US)

Publications by Year

Research Areas

Lymphoma Diagnosis and Treatment, Radiopharmaceutical Chemistry and Applications, Monoclonal and Polyclonal Antibodies Research, Medical Imaging Techniques and Applications, Lung Cancer Treatments and Mutations

Most-Cited Works

→ Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma(2007)1,332 cited
→ Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma(2002)1,164 cited
→ Langerhans cell histiocytosis(1999)720 cited
→ Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma(2002)649 cited
→ Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+B-Cell Non-Hodgkin's Lymphoma(1999)538 cited
→ Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL(2017)411 cited

→ Response Assessment of Aggressive Non-Hodgkin’s Lymphoma by Integrated International Workshop Criteria and Fluorine-18–Fluorodeoxyglucose Positron Emission Tomography(2005)387 cited

→ The NANETS Consensus Guidelines for the Diagnosis and Management of Poorly Differentiated (High-Grade) Extrapulmonary Neuroendocrine Carcinomas(2010)348 cited

→ Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin’s Lymphoma(2003)290 cited

→ A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia(2003)279 cited